HAEMATOLOGICAL MALIGNANCY

This trial is testing if a drug called alectinib, already approved for a type of lung cancer, can help treat other rare cancers that share the same genetic change (ALK mutation). It will involve about 30 adults and children with various rare or hard-to-treat cancers. The goal is …

This study is testing a personalized approach to dosing an antifungal drug called voriconazole for patients with blood cancer. It compares using a patient's genetic test results to guide dosing against the current standard method. The goal is to see if the personalized method hel…

This trial is testing if a drug called capmatinib, already used for some lung cancers, can help adults with rare or uncommon cancers that have specific changes in a gene called MET. The goal is to see if the drug shrinks tumors or provides long-term benefit for these hard-to-trea…

This UK trial is testing whether existing targeted cancer drugs can help patients with rare cancers or common cancers that have rare genetic mutations. The study will enroll 825 adults, teenagers, and children whose cancer has progressed after standard treatments and has a specif…

This UK trial is testing if a drug combination already approved for breast cancer can help control other cancers with a specific genetic feature. It aims to treat adults and children (12+) with rare cancers or common cancers that have a rare genetic change called HER2. The goal i…

This trial is testing if a combination of two drugs, already approved for a type of skin cancer, can help control other rare cancers that share the same genetic change (a BRAF V600 mutation). It aims to enroll 30 adult patients with various rare or uncommon cancers to see if the …

This trial is testing if a drug called entrectinib, already approved for some lung cancers, can help control other rare cancers that share the same genetic change (called ROS1-positive). It aims to enroll about 30 adults and children with these rare cancers to see if the drug shr…

This early-stage study is testing a new drug called CCS1477 (inobrodib) in patients with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to check if the drug is safe, what side effects it causes, and if it shows signs of …